Biotech grants in the United States
Explore Biotech grants for companies in the United States. This list brings together funding for drug discovery, diagnostics, cell and gene therapy, biomanufacturing and life-science research from US innovation agencies, research funders and foundations, international programs open to applicants in the United States, and competitions any company can enter, with the deadline, award size and eligibility on every listing. Grants aimed at Biotech in the United States come first.
Showing 985-1,008 of 1,239 grants
High Priority HIV and Substance Use Research (R01)
NIH · United States
Funds research where HIV and drug use intersect. Preliminary data are compulsory, and the work must sit on NIH's published HIV priorities.
Opportunities for Collaborative Research at the NIH Clinical Center
NIH · United States
Funds a translational research project run jointly with NIH's own intramural investigators at the Clinical Center, up to $500,000.
Cutting-Edge Basic Research Awards (CEBRA)
NIH · United States
Funds high-risk addiction research that is sparse or absent from the institute's current portfolio — a revolutionary method, or a hypothesis with no precedent.
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System
NIH · United States
Funds a biologic for a nervous system disorder from lead optimisation to phase I, with NIH-paid manufacturing and tox work — and the applicant keeps the IP.
Investigator Initiated Innovation in Computational Genomics and Data Science (R01)
NIH · United States
Funds computational genomics work — new analytical methods, early-stage tools, or hardening software the genomics community already relies on.
Investigator Initiated Innovation in Computational Genomics and Data Science (R21)
NIH · United States
Funds the exploratory version of the same computational genomics work — new methods, early tools, or hardening software the field depends on.
Integrating Biospecimen Science Approaches into Clinical Assay Development
NIH · United States
Funds research into how preanalytical handling of biopsies and other biospecimens distorts biomarker results used in clinical assays.
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research
NIH · United States
Funds research using a screening trial's biorepository — serial blood samples collected before diagnosis, with decades of matched participant data.
NIDCD Research Grants for Translating Basic Research into Clinical Practice
NIH · United States
Funds translational research turning basic findings into clinical tools for communication disorders, with practical clinical impact required.
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33)
NIH · United States
Funds early-stage testing of a novel-mechanism drug or a device for mental disorders, designed to show a dose-dependent effect on the target.
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33)
NIH · United States
Funds a feasibility phase then a testing phase for a novel-mechanism drug or a device for mental disorders, with milestones between them.
Early-Stage Development of Informatics Technologies for Cancer Research and Management
NIH · United States
Funds early-stage development of new cancer-research software tools, from first prototype to their first real users.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery
NIH · United States
Funds building animal and tissue models that behave enough like a real neurological disease to test drugs against.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification
NIH · United States
Funds building the assays and running the screens that find drug candidates for neurological disease — the on-ramp to NIH's Blueprint network.
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
NIH · United States
Funds the pharmacology and animal efficacy work that shows a neurological drug candidate is worth developing further.
Basic Research in Cancer Health Disparities (R21)
NIH · United States
Funds early-stage mechanistic work on the biological and genetic causes of cancer health disparities, on a shorter and smaller footing.
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01)
NIH · United States
Funds new screening tests or treatments for serious newborn conditions — including ones not yet on any screening panel.
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21)
NIH · United States
Funds the exploratory version of the same work on screening tests and treatments for serious newborn conditions.
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment
NIH · United States
Funds academic-industry partnerships that turn a lab discovery into a working diagnostic or treatment tool, without a clinical trial attached.
Basic Research in Cancer Health Disparities (R01)
NIH · United States
Funds basic mechanistic research into the biological and genetic causes of cancer health disparities — and into building the tools that research needs.
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies
NIH · United States
Funds mechanistic work on the lasting harms cancer therapy causes, and on turning that understanding into ways to prevent them.
Exploratory/Developmental Bioengineering Research Grants (EBRG)
NIH · United States
Funds early feasibility work on a new biomedical tool, instrument or method that could improve research, care delivery or accessibility.
Mood and Psychosis Symptoms during the Menopause Transition (R01)
NIH · United States
Funds translational work on the neurobiology behind mood and psychotic symptoms during the menopause transition, aimed at treatment targets.
Mood and Psychosis Symptoms during the Menopause Transition (R21)
NIH · United States
Funds the exploratory version of the same translational work on mood and psychotic symptoms during the menopause transition.